X

Hikal Ltd Stock Analysis

Small Cap
Evaluated by 929 users | BSE: 524735 | NSE: HIKAL |
Pharmaceuticals & Drugs
Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 8.39%13.04%10.35%11.92%7.84%8.04%9.39%9.11%10.84%9.12%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 4946946608298729261,0141,2961,5901,507
Y-o-Y Gr. Rt.-40.7%-4.9%25.6%5.1%6.2%9.5%27.8%22.7%-5.2%
Adjusted EPS (Rs.) 3.755.994.696.233.373.485.916.488.657.67
Y-o-Y Gr. Rt.-59.7%-21.7%32.8%-45.9%3.3%69.8%9.6%33.5%-11.3%
Book Value per Share (Rs.) 25.3328.4827.8532.3434.6437.2549.0754.2961.3366.22
Adjusted Net Profit 46.273.857.876.841.642.972.979.810794.5
Net Op. Cash Flow (Rs. Cr.) 11313761.3155102186163139186285
Debt to Cash Flow from Ops 4.473.169.523.535.352.723.664.583.562.26
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Hikal Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 13.2%11.6%14.1%-5.2%
Adjusted EPS 8.3%17.9%9.1%-11.3%
Book Value per Share 11.313.810.58
Share Price 19.2% 11.8% 3.2% 27.9%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 11.2716.7512.6816.0587.8112.4612.5314.9612.02
Operating Profit Margin (%) 24.7827.3328.0324.7821.1119.7919.7618.9419.0818.13
Net Profit Margin (%) 9.3710.638.759.264.774.637.196.166.716.27
Debt to Equity 1.621.441.71.371.281.10.990.950.870.79
Working Capital Days 285222254218233229218206203226
Cash Conversion Cycle 110699195107102106107105113
Entity Percentage Holding
Promoters 68.77%
Institutions 5.59%
Non-Institutions 25.64%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Hikal Ltd's performance infers:

Hikal Ltd earnings have grown by 17.9%, whereas share price has appreciated 11.8% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Hikal Ltd share prices over the last 10 years. Here is what we found out:

Hikal Ltd share price has appreciated 13.9% annually over the past ten years.

Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA.

Hikal is a company built on enduring relationships. They are committed to delivering value as a

Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA.

Hikal is a company built on enduring relationships. They are committed to delivering value as a complementary partner. By delivering on this commitment, they have earned the respect and recognition of leading companies from around the world.

Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries. It collaborates with innovator companies and offer solutions in Contract Research, Custom Synthesis and Custom Manufacturing. Its people have extensive expertise in multi-disciplinary project management.

  • Discovery Research Support It supplies molecules for discovery research on a contract basis. It is the preferred partner of leading multinational companies in different phases of new drug discovery and development. Backed by state-of-the-art instrumentation and an experienced team of scientists, we focus on research on new molecules.
  • Process Development It has a successful track record in developing non-infringing processes and scaling them up from laboratory to kilo scale to commercial scale production. Its engineering expertise enables it to successfully set up chemical plants, manage and develop a wide range of processes that conform to stringent quality and safety guidelines.
  • Analytical Method Development It undertakes method validation of new substances. The activities include in-process analysis, identification and quantification of impurities.
  • Custom Manufacturing It also undertakes custom manufacturing of key intermediates and active substances for pharmaceutical and agrochemical companies worldwide. Its intermediates are being used in new candidate drugs in Phase 1, Phase 2 and Phase 3 stage of clinical trials as well as in commercialized drugs.

Products of the company include:

  • Pharmaceuticals Products: Gabapentin  ,Bupropion Hydrochloride ,Gemfibrozil, Pentoxifylline, Ondansetron Hydrochloride , Ondansetron Base, Triprolidine Hydrochloride ,Acebutolol Hydrochloride, Cinnarizine ,Flunarizine Hydrochloride and Levetiracetam
  • Agrochemicals Products: Diuron ,Ethion ,Isoproturon  ,Metoxuron  ,Quinalphos and Thiabendazole 

Different divisions of the company are:

Pharmaceuticals Division

Hikal is a partner of choice to the global pharmaceutical industry. They support the pharmaceutical industry from the early lead generation stage till the launch of new chemical entities. Hikal's specialization spans the entire spectrum from conventional synthesis to complex chiral chemistry and is backed by state-of-the-art analytical facilities.

Agrochemicals Division

They are the preferred choice of leading Crop Protection companies in the world. Multinational companies leverage their expertise in developing non-infringing processes for molecules and analytical development.

R&D Division:

R&D is a core competency of Hikal. They assign top most priority to investments in world-class scientists and laboratory instrumentation. Their R&D team is mentored by a Scientific Advisory Board of eminent scientists.

They have an impressive R&D record. Their scientists have published several publications and received patents. They have developed several innovative and cost effective processes for several well known APIs.

Hikal has a global footprint. Its presence in strategic markets enables it to serve the customers better. Hikal has a majority stake in Marsing & Co A/S, a key player in the marketing of Active Pharmaceutical Ingredients (APIs) and raw materials for pharma majors and the chemical industry. Based in Denmark, the company has a distribution network in 100 countries across Europe, Latin America, Africa and the Middle East.

Awards & Achievements:

The companies facilities are ISO 17025, ISO 9000-2000, ISO 14001 and OHSAS 18001 certified.

Recent developments

The domestic credit rating agency, ICRA has assigned LBBB+ to Rs 1,017.4 million and $ 33.1 million long term loans of HIKAL. ICRA has assigned LBBB+ rating outstanding on the Rs. 650 million fund-based bank limits of HIKAL. ICRA also has assigned A2 rating outstanding on the Rs 1,210 million fund based and Rs 480 million non-fund based bank limits.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback